This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Arimidex

AstraZeneca PLC

Drug Names(s): anastrozole

Description: Arimidex (anastrozole) is an orally available non-steroidal aromatase inhibitor. Aromatase, a cytochrome P450-dependent enzyme, acts at the last step in the synthesis of estrogen, catalyzing the conversion of androgens to estrogens. Many breast cancers have estrogen receptors, and growth of these tumors can be stimulated by estrogen. Arimidex can decrease estrogen levels which can lead to decreased tumor mass or delayed progression of tumor growth in estrogen sensitive breast cancers.

Deal Structure: In July 2002, Serono entered into an exclusive worldwide agreement with AstraZeneca pursuant to which Serono had the right to develop, register and market Arimidex. Arimidex is currently sold by AstraZeneca in approximately 100 countries worldwide.

In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business with the former Merck KGaA Ethicals Division was completed. Merck Serono is now the division of Merck KGaA which specializes in prescription pharmaceuticals. Its North American business operates in the United States and Canada under EMD Serono.

Partners: Merck KGaA


Arimidex News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug